Tumor/NN
necrosis/NN
factor/NN
alpha/NN
decreases/VBZ
,/,
and/CC
interleukin-10/NN
increases/VBZ
,/,
the/DT
sensitivity/NN
of/IN
human/JJ
monocytes/NNS
to/TO
dexamethasone/NN
:/:
potential/JJ
regulation/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
./.

Resistance/NN
to/TO
glucocorticoid/NN
therapy/NN
has/VBZ
been/VBN
observed/VBN
in/IN
patients/NNS
with/IN
autoimmune/inflammatory/JJ
diseases/NNS
and/CC
may/MD
be/VB
related/JJ
to/TO
the/DT
inflammatory/JJ
process/NN
itself/PRP
./.
=====
The/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
examine/VB
the/DT
ability/NN
of/IN
tumor/NN
necrosis/NN
factor/NN
alpha/NN
(/(
TNFalpha/NN
,/,
a/DT
proinflammatory/JJ
cytokine/NN
)/)
and/CC
interleukin/NN
(/(
IL/NN
)/)
-10/CD
(/(
an/DT
anti-inflammatory/JJ
cytokine/NN
)/)
to/TO
differentially/RB
regulate/VB
the/DT
sensitivity/NN
of/IN
human/JJ
monocytes/macrophages/NNS
to/TO
glucocorticoids/NNS
./.
=====
To/TO
accomplish/VB
this/DT
,/,
we/PRP
first/RB
analyzed/VBD
the/DT
pattern/NN
of/IN
TNFalpha/NN
and/CC
IL-10/NN
inhibition/NN
by/IN
dexamethasone/NN
in/IN
LPS-stimulated/JJ
whole-blood/JJ
cell/NN
cultures/NNS
./.
=====
Second/RB
,/,
we/PRP
studied/VBD
the/DT
modulation/NN
of/IN
the/DT
sensitivity/NN
of/IN
these/DT
cells/NNS
to/TO
dexamethasone/NN
by/IN
preincubation/NN
with/IN
TNFalpha/NN
or/CC
IL-10/NN
and/CC
measurement/NN
of/IN
LPS-stimulated/JJ
IL-6/NN
secretion/NN
./.
=====
In/IN
addition/NN
,/,
we/PRP
evaluated/VBD
the/DT
effect/NN
of/IN
dexamethasone/NN
on/IN
phorbolmyristate-acetate-stimulated/JJ
IL-1/NN
receptor/NN
antagonist/NN
secretion/NN
by/IN
the/DT
human/JJ
monocytic/JJ
cell/NN
line/NN
U937/NN
./.
=====
Finally/RB
,/,
we/PRP
investigated/VBD
whether/IN
the/DT
modulation/NN
of/IN
corticosensitivity/NN
in/IN
TNFalpha-/NN
and/CC
IL-10-pretreated/JJ
U937/NN
cells/NNS
was/VBD
related/JJ
to/TO
a/DT
change/NN
of/IN
the/DT
glucocorticoid/NN
receptor/NN
concentration/NN
and/CC
affinity/NN
./.
=====
Dexamethasone/NN
had/VBD
different/JJ
effects/NNS
on/IN
LPS-induced/JJ
TNFalpha/NN
and/CC
IL-10/NN
secretion/NN
;/:
whereas/IN
it/PRP
suppressed/VBD
TNFalpha/NN
in/IN
a/DT
dose-dependent/JJ
fashion/NN
,/,
its/PRP$
effect/NN
on/IN
IL-10/NN
secretion/NN
was/VBD
biphasic/JJ
,/,
producing/VBG
stimulation/NN
at/IN
lower/JJR
,/,
and/CC
inhibition/NN
at/IN
higher/JJR
doses/NNS
./.
=====
The/DT
concentration/NN
of/IN
LPS/NN
employed/VBN
influenced/VBD
the/DT
effect/NN
of/IN
dexamethasone/NN
on/IN
IL-10/NN
secretion/NN
(/(
P/NN
</JJR
0.001/CD
)/)
./.
=====
Pretreatment/NN
with/IN
TNFalpha/NN
diminished/VBD
,/,
and/CC
with/IN
IL-10/NN
improved/VBD
,/,
the/DT
ability/NN
of/IN
dexamethasone/NN
to/TO
suppress/VB
IL-6/NN
secretion/NN
in/IN
whole-blood/JJ
cell/NN
cultures/NNS
(/(
P/NN
</JJR
0.01/CD
for/IN
both/DT
)/)
and/CC
to/TO
enhance/VB
IL-1/NN
receptor/NN
antagonist/NN
secretion/NN
by/IN
U937/NN
cells/NNS
(/(
P/NN
</JJR
0.05/CD
for/IN
both/DT
)/)
./.
=====
TNFalpha/NN
decreased/VBD
(/(
P/NN
</JJR
0.001/CD
)/)
,/,
while/IN
IL-10/NN
increased/VBD
(/(
P/NN
</JJR
0.001/CD
)/)
,/,
the/DT
concentration/NN
of/IN
dexamethasone/NN
binding/NN
sites/NNS
in/IN
these/DT
cells/NNS
,/,
with/IN
no/DT
discernible/JJ
effect/NN
on/IN
their/PRP$
binding/NN
affinity/NN
./.
=====
We/PRP
conclude/VBP
that/IN
glucocorticoids/NNS
differentially/RB
modulate/VBP
TNFalpha/NN
and/CC
IL-10/NN
secretion/NN
by/IN
human/JJ
monocytes/NNS
in/IN
a/DT
LPS/NN
dose-dependent/JJ
fashion/NN
and/CC
that/IN
the/DT
sensitivity/NN
of/IN
these/DT
cells/NNS
to/TO
glucocorticoids/NNS
is/VBZ
altered/VBN
by/IN
TNFalpha/NN
or/CC
IL-10/NN
pretreatment/NN
;/:
TNFalpha/NN
blocks/VBZ
their/PRP$
effects/NNS
,/,
whereas/IN
IL-10/NN
acts/VBZ
synergistically/RB
with/IN
glucocorticoids/NNS
./.
=====
This/DT
is/VBZ
accompanied/VBN
by/IN
opposite/JJ
glucocorticoid/NN
receptor/NN
changes/NNS
,/,
respectively/RB
opposing/VBG
and/CC
favoring/VBG
glucocorticoid/NN
actions/NNS
./.
=====
This/DT
study/NN
suggests/VBZ
that/IN
the/DT
pattern/NN
of/IN
pro-/antiinflammatory/JJ
cytokine/NN
secretion/NN
may/MD
alter/VB
the/DT
response/NN
of/IN
patients/NNS
to/TO
glucocorticoid/NN
therapy/NN
./.